Physician profile
Michael A Layden
NPI 1194728774
$1,845.04
in general payments reported to CMS, 2019-2025
24 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $47.47 · 2021: $18.48 · 2023: $569 · 2024: $368 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $202.64 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.13 | 2019-2025 | Lifevest |
| Baxter Healthcare | $151.06 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $150.57 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.09 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $137.74 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $129.60 | 2023 | |
| Janssen Pharmaceuticals, INC | $96.93 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $84.27 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $76.53 | 2019-2023 | Evkeeza |
| Merck Sharp & Dohme LLC | $75.34 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $64.97 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $53.03 | 2024-2025 | Wainua |
| Kiniksa Pharmaceuticals International, Plc | $49.12 | 2024 | Arcalyst |
| Amgen INC. | $48.08 | 2019-2023 | Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.63 | 2023 | Cardiomems |
| Kiniksa Pharmaceuticals, LTD. | $38.30 | 2023 | Arcalyst |
| Cvrx, INC. | $33.00 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $28.61 | 2024-2025 | Bodyguardian |
| Actelion Pharmaceuticals US, INC. | $19.94 | 2024 | Uptravi |
| Medtronic, INC. | $18.48 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.79 | 2025 | Onpattro |
| Bridgebio Pharma, INC. | $16.32 | 2025 | Attruby |
| Novo Nordisk INC | $15.87 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Layden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.